Look at Your Therapeutic Strategy Through the Lens of Energy Metabolism Across a Range of Disease Areas

To confidently develop safe and effective therapies, you must understand the full biology of your cells. Incorporating cellular metabolism analysis into your studies lets you be certain about your target’s effects on cell function—and can prevent you from missing potential targets.

In this publication index, you’ll discover how researchers are building robust drug discovery pipelines using metabolic measurements for disease modeling, phenotype assays, target identification and validation, mechanism of action, and lead discovery. We’ve organized it by disease type, so you can quickly locate the sources relevant to your application.

Cancer
Research Immuno‑Oncology/
Immunotherapy Neurodegenerative
Diseases Diabetes, Cardio, and Acquired
Metabolic Disorders Disease
Modeling

• Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer
• Clinical, molecular, metabolic, and immune features are associated with oxidative phosphorylation in melanoma brain metastases
• A potent and selective small molecule inhibitor of myoferlin attenuates colorectal cancer progression
• Hypoxia-induced FOXO4/LDHA axis modulates gastric cancer cell glycolysis and progression
• NIK promotes metabolic adaptation of glioblastoma cells to bioenergetic stress

• PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
• Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes
• The IL-33/ST2 axis affects tumor growth by regulating mitophagy in macrophages and reprogramming their polarization
• T cell-specific deletion of Pgam1 reveals a critical role for glycolysis in T cell responses
• Cytoplasmic Citrate Flux Modulates the Immune Stimulatory NKG2D Ligand MICA in Cancer Cells

• Arrayed CRISPR reveals genetic regulators of tau aggregation, autophagy, and mitochondria in an Alzheimer’s disease model
• The Parkinson’s disease-associated gene ITPKB protects against alpha-synuclein aggregation by regulating ER-to-mitochondria calcium release
• The overexpression of TDP-43 in astrocytes causes neurodegeneration via a PTP1B-mediated inflammatory response
• Cognitive impairment is associated with mitochondrial dysfunction in peripheral blood mononuclear cells of elderly populations
• BNIP3L/NIX-mediated mitophagy protects against glucocorticoid-induced synapse defects

• Improvement of obesity-associated disorders by a small-molecule drug targeting mitochondria of adipose tissue macrophages
• Induction of UCP1 and thermogenesis by a small molecule is achieved via AKAP1/PKA modulation
• TET1 is a beige adipocyte-selective epigenetic suppressor of thermogenesis
• The PD-1 pathway regulates ILC2 metabolism, and PD-1 agonist treatment ameliorates airway hyperreactivity
• Involvement of NDPK-B in Glucose Metabolism-Mediated Endothelial Damage via Activation of the Hexosamine Biosynthesis Pathway and Suppression of O-GlcNAcase Activity

• pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model
• SIRT5 deficiency enhances the proliferative and therapeutic capacities of adipose-derived mesenchymal stem cells via metabolic switching
• Bioenergetic Crosstalk between Mesenchymal Stem Cells and various Ocular Cells through the intercellular trafficking of Mitochondria
• Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics
• The ATP synthase inhibition induces an AMPK-dependent glycolytic switch of mesenchymal stem cells that enhances their immunotherapeutic potential